UTMB Galveston Boosts ZEVASKYN Availability in the Gulf Coast Region
Access to advanced gene therapy for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB) in Texas just took a meaningful step forward. Abeona Therapeutics announced today the activation of The University of Texas Medical Branch (UTMB) in Galveston as a new Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel). This move marks an important expansion for patients needing specialized care for a life-altering and rare skin disorder.
New Options for RDEB Patients in Texas and Beyond
UTMB brings a storied history as Texas’ first dermatology department and is recognized for its expertise in managing complex skin diseases. The newly activated QTC means RDEB patients across Texas and the Gulf Coast region now have increased access to ZEVASKYN—currently the only FDA-approved autologous cell sheet-based gene therapy for wounds caused by RDEB.
RDEB patients have historically faced chronic, painful wounds, with limited options for long-term relief. By partnering with UTMB, Abeona aims to provide local and regional access to this new therapy, lessening the need for burdensome travel and accelerating the potential for life-improving treatment.
ZEVASKYN Offers a New Approach to a Rare Genetic Disorder
RDEB stems from a genetic defect in both copies of the COL7A1 gene, leading to insufficient production of type VII collagen. This causes fragile skin and recurrent, often debilitating wounds. ZEVASKYN addresses the disease at its root—using a patient’s own skin cells, modified outside the body with a working COL7A1 gene and returned as cellular sheets to the wound. Clinical trials have shown that a single surgical application of ZEVASKYN can drive meaningful wound healing and reduce pain, potentially changing the outlook for both pediatric and adult RDEB patients.
| Aspect | Details |
|---|---|
| Indication | Wound treatment for adult and pediatric RDEB patients |
| Therapy Type | Autologous cell sheet-based gene therapy |
| Key Ingredient | Gene-modified cells expressing functional type VII collagen |
| Qualified Treatment Center | UTMB, Galveston, Texas |
| Most Common Side Effects | Pain from procedure, itching |
| Major Risks | Potential allergic reactions, rare risk of cancer, infection transmission |
Patient Support Extends Beyond Treatment
Recognizing the complexity of rare disease management, Abeona offers patient support through its Abeona Assist program. This initiative guides patients through insurance navigation, financial assistance, and logistical challenges related to ZEVASKYN treatment, reinforcing the company’s focus on making innovative therapy truly accessible.
Key Takeaways: Milestone for RDEB Care in Texas
The activation of UTMB as a QTC represents a strategic leap in regional availability of advanced gene therapy. For patients and caregivers dealing with RDEB’s daily realities, ZEVASKYN may offer the most meaningful hope yet for real improvement in wound healing and quality of life. While questions around long-term safety and the risk profile of gene therapies persist, this expansion highlights both progress in rare disease treatment and the importance of accessible care infrastructure.
Those seeking more details about ZEVASKYN access or Abeona Assist can visit www.abeonaassist.com or call 1-855-223-6621.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI